Cinacalcet cost and utility in dialysis patients [3]

Seminars in Dialysis

Volumn 18, Issue 4, 2005, Pages 353-354

  Cohen, Eric ^a   Uribarri, Jaime ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

BLOOD; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; ECONOMICS; HUMAN; LETTER; ORAL DRUG ADMINISTRATION; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM;

ADMINISTRATION, ORAL; CALCIUM; DRUG THERAPY, COMBINATION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PHOSPHORUS; RENAL DIALYSIS; VITAMIN D;

EID: 23844451400     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.18417.x     Document Type: Letter

References (4)

1. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCL, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized double blind multicenter study. J Am Soc Nephrol 16:800-807, 2005
2. Curhan G: Fooling the parathyroid gland - will there be health benefits? N Engl J Med 350:1565-1567, 2004
3. Cohen EP: Reduction in use of parathyroidectomy. J Am Soc Nephrol 14:684a, 2003
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004